<DOC>
	<DOC>NCT01562821</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.</brief_summary>
	<brief_title>Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Cirrhosis (ChildTurcotte Score A, B, or C) Scheduled to undergo partial hepatectomy due to liver cancer or benign tumours Portal vein thrombosis Clinically documented DVT (deep venous thrombosis) Clinically documented symptoms of severe cardiovascular disease and/or previous myocardial/pulmonary infarction or stroke Present renal insufficiency requiring dialysis</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>